Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?

We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the most promising stocks on our list.

TheFly reported on June 3 that BofA Securities analyst Jason Zemansky increased the price target on RCKT to $10 from $9 while maintaining a Buy rating on the shares. The analyst viewed the company's first-quarter update positively, highlighting the restart of RP-A501 dosing as an important step in Rocket Pharmaceuticals' near-term recovery strategy and development progress.

In a separate major operational milestone on June 12, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million. The voucher was awarded by the FDA in March 2026 following the approval of Kresladi, Rocket's gene therapy for severe leukocyte adhesion deficiency-I, a rare and potentially life-threatening immune disorder.

Before the transaction, RCKT reported cash, cash equivalents, and investments of $144.4 million as of March 31, 2026. Following the non-dilutive proceeds from the PRV sale, the company's pro forma cash position increased to approximately $322.6 million, extending its expected operational runway through the second quarter of 2028.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company developing one-time gene therapies aimed at treating rare pediatric diseases, with a focus on potentially curative treatments and advancing toward commercialization.

While we acknowledge the potential of RCKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.